CN100502890C - Amoxicillin antibacterial agent containing nano silver and preparation method thereof - Google Patents
Amoxicillin antibacterial agent containing nano silver and preparation method thereof Download PDFInfo
- Publication number
- CN100502890C CN100502890C CNB2006100243085A CN200610024308A CN100502890C CN 100502890 C CN100502890 C CN 100502890C CN B2006100243085 A CNB2006100243085 A CN B2006100243085A CN 200610024308 A CN200610024308 A CN 200610024308A CN 100502890 C CN100502890 C CN 100502890C
- Authority
- CN
- China
- Prior art keywords
- amoxicillin
- silver
- solution
- nanometer silver
- nanometer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title claims abstract description 71
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 title claims abstract description 61
- 229960003022 amoxicillin Drugs 0.000 title claims abstract description 61
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000003242 anti bacterial agent Substances 0.000 title claims description 16
- 229910052709 silver Inorganic materials 0.000 claims description 64
- 239000004332 silver Substances 0.000 claims description 64
- 239000000243 solution Substances 0.000 claims description 25
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 239000000084 colloidal system Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000003760 magnetic stirring Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims 8
- 229910001961 silver nitrate Inorganic materials 0.000 claims 4
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims 2
- 230000006837 decompression Effects 0.000 claims 2
- 230000000845 anti-microbial effect Effects 0.000 abstract description 18
- 238000012360 testing method Methods 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 33
- 230000003115 biocidal effect Effects 0.000 description 14
- 229940088710 antibiotic agent Drugs 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 150000003952 β-lactams Chemical class 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 3
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 229960003324 clavulanic acid Drugs 0.000 description 2
- 238000005137 deposition process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 sulfonamides compound Chemical class 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000000713 high-energy ball milling Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 238000000593 microemulsion method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to an amoxicillin antimicrobial containing nano silver. its preparation method and application. At the normal temperature the nano silver and amoxicillin are uniformly mixed so as to obtain the invented amoxicillin antimicrobial containing nano silver. The tests show that said invention has stronger antimicrobial effect.
Description
Technical field
The invention belongs to the biological medicine technology field, be specifically related to a kind of amoxicillin antibacterial agent that contains nanometer silver and preparation method thereof.
Background technology
(β-lactam) and sulfonamides compound are broad-spectrum antibiotics comparatively to β-lactams.Because long-time application repeatedly causes a large amount of antibacterials to the strong Drug resistance of this type of antibacterial generation, thereby in life neutralization medical treatment, adopts the antimicrobial dosage of increase to reach satisfied antibacterial effect usually.The consequence of doing like this can only be the Drug resistance that constantly increases antibacterial, and the Drug resistance of antibacterial more and more becomes the serious problems that influence human health and life.In recent years, people study the drug-fast mechanism of antibacterial, (amount of β-lactamases) is relevant to the Drug resistance of β-lactams and the beta-lactam hydrolytic enzyme of its generation to find antibacterial, beta-lactam hydrolytic enzyme hydrolyzable 'beta '-lactam antibiotic, make it can not destroy the synthetic of cell wall, thereby make its forfeiture drug effect.In order to satisfy medical treatment and needs in life, medicament scholar and physician are constantly developed new 'beta '-lactam antibiotic from various different angles, as the part-structure of the non-effective site by changing beta-lactam, make medicament present inertia, thereby avoid hydrolysis and lost efficacy hydrolytic enzyme; (or replacing) uses two kinds of antibiotics simultaneously, and its principle is after antibacterial develops immunity to drugs to a kind of antibiotics, another antibiotic kills antibacterial; Add some auxiliary Organic substances in antibiotics, as clavulanic acid (Clavulanic acid), these auxiliary elements can suppress β-lactams fermentoid, thereby the drug effect of antibiotics is brought into play.These methods have solved drug-fast problem to a certain extent, but the drug effect of the antibacterial of failing to improve significantly, and particularly along with the entering of some organic component, medicine also increases the side effect of human body thereupon.In human with natural fight, find to have material in many mineral and the biology, as sulfur, silver, chitosan, hydroxyapatite or the like with antibacterial action.Over nearly 20 years, along with the birth and the development of nanosecond science and technology, the pleasantly surprised discovery of people has multiple nano-particle also to have antibacterial action preferably, as nanometer gold, nanometer silver, nano titanium oxide, nanometer hydroxyapatite.Therefore, biodegradable nontoxic nano grade biological antibacterial or inorganic low (or do not have) toxic nano-particle and the associating of conventional antibiotic is antibiotic, be those skilled in the art's goal in research with the antibiotic poor efficiency of effective solution.
Summary of the invention
The objective of the invention is to propose a kind of amoxicillin antibacterial agent that contains nanometer silver and preparation method thereof.
A kind of amoxicillin antibacterial agent that contains nanometer silver that the present invention proposes, amoxicillin solution and nanometer silver mix, wherein, the solution of the powder preparation in the Amoxicillin Capsules is adopted in the amoxicillin, the nanometer silver particle diameter is 10-50nm, and the mass ratio of amoxicillin and nanometer silver is 50: 1-10: 1.
The preparation method of the amoxicillin antibacterial agent that contains nanometer silver that the present invention proposes at normal temperatures, is mixed in proportion the solution of the preparation of the powder in the Amoxicillin Capsules and the silver colloid dispersion liquid of nanometer silver, stirs 8-20 minute, promptly gets required product.
Among the present invention, described nanometer silver can utilize soluble silver salt, adopts several different methods such as sol-gel processing, microemulsion method, reverse micelle method, vapour deposition process to obtain, and is easy to prepare, also can be by commercially available acquisition (commercialization).Used nanometer silver prepares by following method among the present invention:
Adopt soluble silver salt, at normal temperatures and pressures, inject ammonia in concentration is the silver salt of 0.01-0.1mol/L, stir, keeping the solution pH value is 11-12, and the response time is 10-15 minutes, obtains silver-colored ammonia ([Ag (NH
3)
2]
+) solution, [Ag (NH
3)
2]
+The sodium lauryl sulphate of solution and 5wt% (SDS) aqueous solution with the volume ratio of 1:0.9-1:1.1 in reaction bulb behind the uniform mixing, placing temperature is on the 60-80 ℃ of magnetic stirring apparatus, dropwise add vitamin C with medical Transfusion device, ascorbic concentration is 0.02mol/L, and the maintenance speed of agitator is 100-130 rev/min, react 1.5-2.5 hour (amount that is slightly larger than in the stoichiometry with ascorbic consumption is as the criterion), obtain the precipitate of black, with ethanol is solvent, the centrifuge washing precipitate to remove surfactant, reduces pressure or vacuum distilling then, temperature is 50-80 ℃, promptly gets nanometer silver.
Among the present invention, the block and the powder body of argent also can be adopted in the silver-colored source of described preparation nanometer silver.As: block or powder body silver are prepared nanometer silver by physical methods such as induced with laser vapour deposition process, mixing plasma method, sputtering method, high-energy ball milling methods.
The amoxicillin antibacterial agent that contains nanometer silver of the present invention is used for escherichia coli, the application that also can be used for Hemolytic streptococcus, streptococcus pneumoniae, do not produce penicillinase gold Portugal bacterium or hemophilus influenza, antibacterials such as proteus mirabilis, Enterococcus presses down (resisting) bacterium.
The method of testing of general anti-biotic material anti-microbial property is adopted in the test of the anti-microbial property of the amoxicillin antibacterial agent that contains nanometer silver that the present invention obtains.In amount of bacteria is 5.0 * 10
6Under the CFU, detect the minimal inhibitory concentration of amoxicillin, nanometer silver respectively; Under same condition, add respectively nanometer silver and amoxicillin the variable concentrations mixed solution and and their compare during use separately.According to the method that Sondi describes, set up their growth curve.
With example, concrete method of testing is to adopt the general antibacterial antiplaque agent performance test methods of microbiology with the test escherichia coli, and test strain (escherichia coli F220) is activated under 37 ℃ in the LB culture medium, is cultured to amount of bacteria then and reaches 10
8～10
9CFU.Then inoculum is carried out sterile working's filtration washing, strain is diluted to obtains 5.0 * 10 in the sterilized water
6The bacteria sample of CFU.
These antibacterials are divided into equal some five equilibriums, add 0mg/ml respectively, 0.150mg/ml, 0.300mg/ml, 0.375mg/ml, the amoxicillin solution of 0.450mg/ml and 0.525mg/ml and 0 μ g/ml, 5 μ g/ml, 10 μ g/ml, 15 μ g/ml, 20 μ g/ml, 25 μ g/ml, 30 μ g/ml, 35 μ g/ml, the nano silver dispersion of 40 μ g/ml was cultivated 24 hours down for 37 ℃ in temperature then.Can detect in amount of bacteria respectively like this is 5.0 * 10
6Under the CFU, the minimal inhibitory concentration of amoxicillin, nanometer silver is about MIC=40 μ g/ml.According to the Sondi method, set up their growth curve.Escherichia coli are added to and contain the 0.15mg/ml amoxicillin respectively, in the 100ml LB fluid medium of 5 μ g/ml nanometer silvers and 0.15mg/ml amoxicillin and 5 μ g/ml nanometer silver mixing antibacterial.The growth curve of antibacterial OD value of bacterial concentration when detecting different time is come definite.
The present invention has the following advantages:
1, the invention provides a kind of to conventional antibacterial, particularly antibacterial to the improvement of its anti-(going out) microbial inoculum that develops immunity to drugs and new approaches, the new way of optimization.That is, on the basis of original medicament, add a small amount of nanometer grade inorganic antibacterial material, implement Synergistic antimicrobial.So not only greatly reduce the dosage of original medicine artificial increase, and, also can reach comparatively ideal sterilization (or antibacterial) effect under the lower situation of original pharmaceutical quantities in order to overcome Drug resistance.
2, the present invention has realized the optimum organization of two kinds of antibacterial, and the two effect sum when using separately that the Synergistic antimicrobial effect significantly is better than Isodose is opportunities of shining new vigor to traditional antibacterials.
3, the present invention is the theme with antibacterial amoxicillin commonly used and the nanometer silver Synergistic antimicrobial that is easy to get, sets forth in detail the theory of Synergistic antimicrobial, the foundation of antibiotic novel pharmaceutical formulation had uses for reference and directive significance.
5, related amoxicillin and nanometer silver Synergistic antimicrobial among the present invention can be prepared into complex antimicrobials comparatively easily, and has raw material and be easy to get, and production technology is simple, and is easy to operate, helps advantages such as industrialization and commercialization.Have the disinfectant that is used for household, medicine, environment, chemical industry and public place and (or) potentiality of antibacterial.Thereby comparatively vast potential for future development and application space arranged.
Description of drawings
The TEM photo of Fig. 1 nanometer silver and ED figure.
The amoxicillin antimicrobial effect curve chart of Fig. 2 variable concentrations.
The nanometer silver antimicrobial effect curve figure of Fig. 3 variable concentrations.
Concentration amoxicillin that Fig. 4 is different and nanometer are separately antibiotic and unite antimicrobial controlled trial figure.Wherein Fig. 4 (A) represents the antibacterial effect block diagram.Fig. 4 (B) is and the corresponding outdoor scene photo of experiment, a among the figure, 5 μ g/ml nanometer silvers, b, 0.15mg/ml amoxicillin, c, 0.15mg/ml amoxicillin+5 μ g/ml nanometer silvers, d, 0.15mg/ml amoxicillin+10 μ g/ml nanometer silvers.
Fig. 5 is the growth curve chart of antibacterial in containing different antibacterial LB culture fluid.Wherein ▲, 5 μ g/ml nanometer silvers, ●, 0.15mg/ml amoxicillin, ■, 0.15mg/ml amoxicillin+5 μ g/ml nanometer silvers.
The specific embodiment
(1) preparation of nanometer silver
At normal temperatures and pressures, to concentration 0.01mol/L AgNO
3Solution injects ammonia, keeps pH value of solution=12, then [Ag (NH
3)
2]+solution and 5% (wt%) sodium lauryl sulphate (SDS) aqueous solution equal-volume is mixed into triangular flask, and placing temperature is on 70 ℃ of magnetic stirring apparatuss.Dropwise add vitamin C (concentration 0.01mol/L) with medical Transfusion device, the rotating speed that keeps stirrer simultaneously is 120 rev/mins, reacts 2 hours.Do solvent centrifuge washing precipitation (repeated several times is removed surfactant) with ethanol, vacuum drying promptly gets nanometer silver then.
(2) nanometer silver and amoxicillin anti-microbial property test (minimal inhibitory concentration test)
In antibacterial test, test strain (escherichia coli F220) is activated under 37 ℃ in the LB culture medium, is cultured to amount of bacteria then and reaches 108～109CFU.Then inoculum is carried out sterile working's filtration washing, strain is diluted to obtains 5.0 * 10 in the sterilized water
6The bacteria sample of CFU.
These antibacterials are divided into equal some five equilibriums, add 0mg/ml respectively, 0.150mg/ml, 0.300mg/ml, 0.375mg/ml, the amoxicillin solution of 0.450mg/ml and 0.525mg/ml and 0 μ g/ml, 5 μ g/ml, 10 μ g/ml, 15 μ g/ml, 20 μ g/ml, 25 μ g/ml, 30 μ g/ml, 35 μ g/ml, the nano silver dispersion of 40 μ g/ml was cultivated 24 hours down for 37 ℃ in temperature then.Can detect in amount of bacteria respectively like this is 5.0 * 10
6Under the CFU, the minimal inhibitory concentration of amoxicillin, nanometer silver.From Fig. 2 and 3 minimal inhibitory concentration MIC=0.525mg/ml of amoxicillin as can be seen; The minimal inhibitory concentration of nanometer silver is about MIC=40 μ g/ml.
(3) nanometer silver and amoxicillin Synergistic antimicrobial performance test and comparison
Under same condition, in the aliquot bacterial strain, add the nanometer silver of 1ml and the variable concentrations mixed solution of amoxicillin respectively, 0.15mg/ml amoxicillin+5 μ g/ml nanometer silvers, as seen in Figure 4, the effect of amoxicillin and nanometer silver Synergistic antimicrobial is far superior to amoxicillin and the independent effect of using of nanometer silver.
(4) antibiotic kinetic test
According to the method that Sondi describes, set up their growth curve.Escherichia coli are added to and contain the 0.15mg/ml amoxicillin respectively, in the 100ml LB fluid medium of 5 μ g/ml nanometer silvers and 0.15mg/ml amoxicillin and 5 μ g/ml nanometer silver mixing antibacterial.The growth curve of antibacterial OD value of bacterial concentration when detecting different time is come definite.
Embodiment 2
Under same condition, in the aliquot bacterial strain, add the nanometer silver of 1ml and the variable concentrations mixed solution of amoxicillin respectively, 0.15mg/ml amoxicillin+10 μ g/ml nanometer silvers, stir and obtained product in 10 minutes, as seen in Figure 4, the effect of amoxicillin and nanometer silver Synergistic antimicrobial is far superior to amoxicillin and the independent effect of using of nanometer silver.
Embodiment 3
(particle diameter is 30-40nm) to be mixed with the silver colloid dispersion liquid of 10 μ g/ml and solution that the powder in the commercially available Amoxicillin Capsules (specification 0.125g/ grain) is mixed with 0.25mg/ml is mixed to utilize commercially available nanometer silver, the mass ratio of nanometer silver and amoxicillin is 1:10, stirred 8 minutes, obtain product, the enforcement associating is antibiotic also to realize satisfactory results.
(particle size range 25-30nm) is mixed with the silver colloid dispersion liquid of 10 μ g/ml and solution that the powder in the commercially available Amoxicillin Capsules (specification 0.125g/ grain) is mixed with 0.25mg/ml is mixed to utilize commercially available nanometer silver, the mass ratio of nanometer silver and amoxicillin is 1:20, stirred 15 minutes, obtain product, the enforcement associating is antibiotic also to realize satisfactory results.
(particle size range 35-40nm) is mixed with the silver colloid dispersion liquid of 10 μ g/ml and solution that the powder in the commercially available Amoxicillin Capsules (specification 0.125g/ grain) is mixed with 0.25mg/ml is mixed to utilize commercially available nanometer silver, the mass ratio of nanometer silver and amoxicillin is 1:40, stirred 25 minutes, obtain product, the enforcement associating is antibiotic also to realize satisfactory results.
(particle size range 25-30nm) is mixed with the silver colloid dispersion liquid of 10 μ g/ml and solution that the powder in the commercially available Amoxicillin Capsules (specification 0.125g/ grain) is mixed with 0.25mg/ml is mixed to utilize commercially available nanometer silver, the mass ratio of nanometer silver and amoxicillin is 1:50, stirred 30 minutes, obtain product, the enforcement associating is antibiotic also to realize satisfactory results.
Claims (2)
1, a kind of amoxicillin antibacterial agent that contains nanometer silver, it is characterized in that mixing by amoxicillin solution and nanometer silver, wherein, the solution of the powder preparation in the Amoxicillin Capsules is adopted in the amoxicillin, the nanometer silver particle diameter is 10-40nm, and the mass ratio of amoxicillin and nanometer silver is 50:1-10:1; Nanometer silver adopts silver nitrate to prepare by following step: at normal temperatures and pressures, inject ammonia in concentration is the silver nitrate of 0.01-0.1mol/L, stir, keeping the solution pH value is 11-12, and the response time is 10-15 minutes, obtains silver-colored ammonia [Ag (NH
3)
2]
+Solution is [Ag (NH
3)
2]
+In reaction bulb behind the uniform mixing, place temperature is on the 60-80 ℃ of magnetic stirring apparatus to the lauryl sodium sulfate aqueous solution of solution and 5wt%, ascorbinate with the volume ratio of 1:0.9-1:1.1, ascorbic concentration is 0.02mol/L, and to keep speed of agitator be 100-130 rev/min, reacted 1.5-2.5 hour, obtains the precipitate of black, with ethanol is solvent, the centrifuge washing precipitate is removed surfactant, then decompression or vacuum distilling, temperature is 50-80 ℃, promptly gets nanometer silver.
2, a kind of preparation method that contains the amoxicillin antibacterial agent of nanometer silver as claimed in claim 1, it is characterized in that at normal temperatures, the solution of the preparation of the powder in the Amoxicillin Capsules and the silver colloid dispersion liquid of nanometer silver are mixed in proportion, stirred 8-20 minute, promptly get required product;
Wherein, nanometer silver adopts silver nitrate to prepare by following step: at normal temperatures and pressures, inject ammonia in concentration is the silver nitrate of 0.01-0.1mol/L, stir, keeping the solution pH value is 11-12, and the response time is 10-15 minutes, obtains silver-colored ammonia [Ag (NH
3)
2]
+Solution is [Ag (NH
3)
2]
+In reaction bulb behind the uniform mixing, place temperature is on the 60-80 ℃ of magnetic stirring apparatus to the lauryl sodium sulfate aqueous solution of solution and 5wt%, ascorbinate with the volume ratio of 1:0.9-1:1.1, ascorbic concentration is 0.02mol/L, and to keep speed of agitator be 100-130 rev/min, reacted 1.5-2.5 hour, obtains the precipitate of black, with ethanol is solvent, the centrifuge washing precipitate is removed surfactant, then decompression or vacuum distilling, temperature is 50-80 ℃, promptly gets nanometer silver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100243085A CN100502890C (en) | 2006-03-02 | 2006-03-02 | Amoxicillin antibacterial agent containing nano silver and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100243085A CN100502890C (en) | 2006-03-02 | 2006-03-02 | Amoxicillin antibacterial agent containing nano silver and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1850113A CN1850113A (en) | 2006-10-25 |
| CN100502890C true CN100502890C (en) | 2009-06-24 |
Family
ID=37131625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100243085A Expired - Fee Related CN100502890C (en) | 2006-03-02 | 2006-03-02 | Amoxicillin antibacterial agent containing nano silver and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100502890C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103042227B (en) * | 2012-12-18 | 2014-12-31 | 广东省微生物研究所 | Nano-silver sol antibacterial agent and preparation method thereof |
| CN103142649B (en) * | 2013-03-01 | 2014-08-20 | 赵华文 | Preparation method of amylose-coated I3<->-complexed silver-coated iron composite nanoparticles |
| CN103933066B (en) * | 2014-03-12 | 2017-05-24 | 同济大学 | Method for improving antibacterial activity of cephalexin through synergy of nanometer copper oxide |
| CN109632661B (en) * | 2018-11-02 | 2021-09-17 | 中南大学 | Gold nanoparticle probe for visually detecting amoxicillin, preparation method and application thereof |
| CN113427015B (en) * | 2021-06-18 | 2022-11-01 | 上海交通大学 | Preparation method and application of a new type of silver nanomaterial AgNFs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1672689A (en) * | 2004-03-26 | 2005-09-28 | 深圳市爱杰特医药科技有限公司 | Nano silver antiseptic gel for treating women's genital tract infection and its prepn and application |
-
2006
- 2006-03-02 CN CNB2006100243085A patent/CN100502890C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1672689A (en) * | 2004-03-26 | 2005-09-28 | 深圳市爱杰特医药科技有限公司 | Nano silver antiseptic gel for treating women's genital tract infection and its prepn and application |
Non-Patent Citations (2)
| Title |
|---|
| 纳米以银抗菌材料研发现状. 张文钲，王广文.化工新型材料，第31卷第2期. 2003 * |
| 纳米银材料抗菌效果研究及其安全性初步评价. 钟金栋，夏雪山，张若愚，高毅颖.昆明理工大学学报(理工版)，第30卷第5期. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1850113A (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ulagesan et al. | Biogenic preparation and characterization of Pyropia yezoensis silver nanoparticles (Py AgNPs) and their antibacterial activity against Pseudomonas aeruginosa | |
| CN105188719A (en) | Metastable silver nanoparticle composites | |
| CN100502890C (en) | Amoxicillin antibacterial agent containing nano silver and preparation method thereof | |
| CN101255274A (en) | Composite nano silver-polyurethane antibacterial material and preparation method thereof | |
| Altaf et al. | Effective inhibition and eradication of pathogenic biofilms by titanium dioxide nanoparticles synthesized using Carum copticum extract | |
| Pansara et al. | Formulation optimization of chitosan-stabilized silver nanoparticles using in vitro antimicrobial assay | |
| CN106424753B (en) | A kind of MnO2The preparation and its application of-Ag nanocomposite | |
| CN111658668B (en) | Functional antibacterial combination medicine and application | |
| CN106377433B (en) | A kind of antibiotic property tooth root canal filling material and preparation method thereof | |
| Duraisamy et al. | Assessment of antimicrobial activity of nanocomposites based on nano-hydroxyapatite (HAP), chitosan, and vitamin K2 | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| CN101756910B (en) | Lung targeting ceftiofur microsphere and preparation method | |
| Nan et al. | Research on the antibacterial properties of nanoscale zinc oxide particles comprehensive review | |
| Hussein et al. | Biogenic synthesized silver nanoparticles for control of multidrug resistant bacteria, and inhibition of NLRP3 inflammasome activation: In-vitro-and in-vivo study | |
| CN102949397B (en) | Cefotaxime sodium and tazobactam sodium preparation for injection and preparing method thereof | |
| CN102198144A (en) | Synergetic method for bacterial inhibition of ceftriaxone sodium by chitosan | |
| Gupta et al. | Synthesis, characterization and concentration dependant antibacterial potentials of nickel oxide nanoparticles against Staphylococcus aureus and Escherichia coli | |
| CN105030819A (en) | Use of 3-hydroxy-4-pyridone high-molecular iron chelating agent | |
| CN103536617A (en) | Ceftazidine composition freeze-dried powder for injection | |
| Hussein et al. | Biosynthesis of Zinc Oxide nanoparticles by Lantana camara flowers extract characterization and their antibacterial potential against pathogenic bacteria isolated from wounds infections. | |
| CN102440982B (en) | Chlorhexidine acetate-copper/imvite nano antibacterial composite material and preparation method thereof | |
| CN103536558A (en) | Cefoperazone sodium composition freeze-dried powder for injection | |
| CN102670620B (en) | Cefradine-borneol composition | |
| CN103585117A (en) | Cefotaxime sodium composition freeze-dried powder for injection | |
| TWI588093B (en) | Method for manufacturing polymer latex particle containing nano silver particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090624 Termination date: 20120302 |